Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alnus rhombifolia pollen is a biologic allergenic extract derived from the white alder tree, native to western North America. It is used clinically for the diagnosis and treatment of Type I hypersensitivity reactions. As a diagnostic agent, it is applied via percutaneous or intradermal injection to elicit a wheal-and-flare reaction in sensitized individuals. In immunotherapy, gradual exposure to the extract is used to induce immunological tolerance. The extract contains proteins that act as allergens, which cross-link specific IgE antibodies bound to FceRI receptors on mast cells and basophils, triggering the release of inflammatory mediators like histamine and leukotrienes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on alnus rhombifolia pollen.